BR112014008555A2 - r(+)-n-formil-propargil-aminoindano - Google Patents

r(+)-n-formil-propargil-aminoindano

Info

Publication number
BR112014008555A2
BR112014008555A2 BR112014008555A BR112014008555A BR112014008555A2 BR 112014008555 A2 BR112014008555 A2 BR 112014008555A2 BR 112014008555 A BR112014008555 A BR 112014008555A BR 112014008555 A BR112014008555 A BR 112014008555A BR 112014008555 A2 BR112014008555 A2 BR 112014008555A2
Authority
BR
Brazil
Prior art keywords
aminoindane
propargyl
formyl
compound
pharmaceutically acceptable
Prior art date
Application number
BR112014008555A
Other languages
English (en)
Portuguese (pt)
Inventor
Frenkel Anton
Licht Danit
Bahar Eliezer
Zholkovsky Marina
Keisar Michal
Safadi Muhammad
Cohen Rachel
Lidor-Hadas Ramy
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112014008555A2 publication Critical patent/BR112014008555A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/03Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112014008555A 2011-10-10 2012-10-09 r(+)-n-formil-propargil-aminoindano BR112014008555A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161545422P 2011-10-10 2011-10-10
PCT/US2012/059356 WO2013055687A2 (en) 2011-10-10 2012-10-09 R(+)-n-formyl-propargyl-aminoindan

Publications (1)

Publication Number Publication Date
BR112014008555A2 true BR112014008555A2 (pt) 2017-04-18

Family

ID=48042235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008555A BR112014008555A2 (pt) 2011-10-10 2012-10-09 r(+)-n-formil-propargil-aminoindano

Country Status (15)

Country Link
US (1) US9346746B2 (enExample)
EP (1) EP2766002A4 (enExample)
JP (1) JP2014534196A (enExample)
KR (1) KR20140090996A (enExample)
CN (1) CN103874487A (enExample)
AR (1) AR088297A1 (enExample)
AU (1) AU2012323349A1 (enExample)
BR (1) BR112014008555A2 (enExample)
CA (1) CA2851276A1 (enExample)
EA (1) EA201490761A1 (enExample)
HK (1) HK1200315A1 (enExample)
IL (1) IL231721A0 (enExample)
MX (1) MX2014004308A (enExample)
WO (1) WO2013055687A2 (enExample)
ZA (1) ZA201403043B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
US20110130466A1 (en) * 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU1867095A (en) * 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69732984T2 (de) 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
EP1242066B1 (en) * 1999-10-27 2006-06-28 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
EP2526944B1 (en) 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
CA2515200C (en) 2003-02-06 2013-10-08 University Of Georgia Research Foundation, Inc. Galacturonosyltransferases, nucleic acids encoding same and uses therefor
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
CN101098685A (zh) 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
KR20140103356A (ko) 2005-02-23 2014-08-26 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
EP1954667B1 (en) 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2008076315A1 (en) 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
ES2389353T3 (es) 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
JP2011522892A (ja) 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
CA2727021A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
WO2009154777A2 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
US20110130466A1 (en) 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
EA201390613A1 (ru) 2010-10-26 2013-11-29 Тева Фармасьютикал Индастриз Лтд. Обогащенный дейтерием расагилин
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
US20130089611A1 (en) 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Also Published As

Publication number Publication date
CN103874487A (zh) 2014-06-18
US9346746B2 (en) 2016-05-24
ZA201403043B (en) 2015-08-26
AR088297A1 (es) 2014-05-21
IL231721A0 (en) 2014-05-28
KR20140090996A (ko) 2014-07-18
NZ624206A (en) 2016-11-25
HK1200315A1 (en) 2015-08-07
MX2014004308A (es) 2014-07-24
WO2013055687A3 (en) 2013-07-25
EA201490761A1 (ru) 2014-11-28
JP2014534196A (ja) 2014-12-18
CA2851276A1 (en) 2013-04-18
EP2766002A4 (en) 2015-07-01
WO2013055687A2 (en) 2013-04-18
EP2766002A2 (en) 2014-08-20
US20130089612A1 (en) 2013-04-11
AU2012323349A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
BR112014008555A2 (pt) r(+)-n-formil-propargil-aminoindano
MY163083A (en) Solid forms of a pharmaceutically active substance
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112013006769A2 (pt) combinação sinérgica de um anticorpo específico para cd38
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
IN2014DN10670A (enExample)
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
IN2014CN03506A (enExample)
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
BR112014019171A8 (pt) Composições intranasais de dexdetomida e seus métodos de uso
MX391043B (es) Formulaciones de anticuerpo y metodos.
ECSP14013179A (es) Compuesto inhibidor de la señalización de la trayectoria notch
CR20130539A (es) Triazolopiridinas
MX2011007763A (es) Metodos y composiciones para tratamiento de cancer de pulmon.
BR112014025041B8 (pt) Composição farmacêutica
MX362879B (es) Usos novedosos.
BR112015006868A2 (pt) composições antibióticas de tazobactam arginina
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
IN2014DN07996A (enExample)
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX337612B (es) Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico.
BR112012026542A2 (pt) abordagem seletiva de tecido
BR112014009760A8 (pt) análogos de ácido siálico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.